First-pass extracted concept

CSF Aβ42/Aβ38 ratio

Candidate: concept label1 source documents4 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

Aβ42/Aβ38

Extracted Explainers

What the tool is doing

This CSF biomarker ratio is presented as a diagnostic marker for Alzheimer disease. The abstract states it outperforms CSF Aβ42 alone for detecting brain amyloid deposition and distinguishing AD dementia from non-AD dementias.

Source 1DOI PubMed

Resources required

Use of this ratio requires CSF sampling and measurement of both Aβ42 and Aβ38. The abstract does not specify the assay platform.

Source 1DOI PubMed

What problem it solves

It addresses the limited specificity of CSF Aβ42 alone for AD-type pathology. The ratio is described as better reflecting AD-type pathology in clinical work-up.

Source 1DOI PubMed

What it does not solve

The abstract does not establish universal cutoffs, assay standardization details, or performance in all dementia subtypes. It also does not describe treatment or disease monitoring use.

Source 1DOI PubMed

Alternatives

The abstract directly contrasts this ratio with CSF Aβ42 alone and also mentions the related CSF Aβ42/Aβ40 ratio.

Source 1DOI PubMed

Evidence Snippets

The CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios are significantly better than CSF Aβ42 to detect brain amyloid deposition in prodromal AD and to differentiate AD dementia from non-AD dementias.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2016Annals of Clinical and Translational NeurologyDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1clinical recommendationsupports2016Source 1DOI PubMed

CSF Aβ42/Aβ40 and CSF Aβ42/Aβ38 ratios should be used rather than CSF Aβ42 alone in the clinical work-up of Alzheimer disease.

Quoted textsource-backed

These findings strongly suggest that the ratios rather than CSF Aβ42 should be used in the clinical work-up of AD.

Claim 2comparative diagnostic performancesupports2016Source 1DOI PubMed

CSF Aβ42/Aβ40 and CSF Aβ42/Aβ38 ratios are significantly better than CSF Aβ42 alone for detecting brain amyloid deposition in prodromal Alzheimer disease.

Quoted textsource-backed

The CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios are significantly better than CSF Aβ42 to detect brain amyloid deposition in prodromal AD

Claim 3comparative diagnostic performancesupports2016Source 1DOI PubMed

CSF Aβ42/Aβ40 and CSF Aβ42/Aβ38 ratios are significantly better than CSF Aβ42 alone for differentiating Alzheimer disease dementia from non-Alzheimer dementias.

Quoted textsource-backed

The CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios are significantly better than CSF Aβ42 to ... differentiate AD dementia from non-AD dementias.

Claim 4pathology specificitysupports2016Source 1DOI PubMed

CSF Aβ42/Aβ40 and CSF Aβ42/Aβ38 ratios reflect AD-type pathology better than CSF Aβ42 alone.

Quoted textsource-backed

The ratios reflect AD-type pathology better, whereas decline in CSF Aβ42 is also associated with non-AD subcortical pathologies.